B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

OBJECTIVE: We previously reported that selective depletion of B-lymphocytes with rituximab, an anti-CD20 monoclonal antibody, slowed decline of β-cell function in recent-onset type 1 diabetes mellitus (T1DM) at 1 year. Subjects were followed further to determine whether there was persistence of effe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pescovitz, Mark D., Greenbaum, Carla J., Bundy, Brian, Becker, Dorothy J., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Marks, Jennifer B., Moran, Antoinette, Raskin, Philip, Rodriguez, Henry, Schatz, Desmond A., Wherrett, Diane K., Wilson, Darrell M., Krischer, Jeffrey P., Skyler, Jay S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2014
Assuntos:
Emerging Technologies and Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3898764/
https://ncbi.nlm.nih.gov/pubmed/24026563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc13-0626
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados